Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Sponsor
Chugai Pharma Taiwan
Study ID
NCT01347983
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

24 week open-labeled extension study to continue monitoring the same group of patients in the previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of tocilizumab.

Key Dates

Start date
May 31, 2011
Status verified
Apr 2013
Primary completion
Mar 31, 2013
Completion
Apr 30, 2013

Study Design

Enrollment
72 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Proportion of patients with an American College of Rheumatology 70 (ACR70) response [ Time Frame: at week 24 ]

Related Studies